Aviragen Therapeutics (AVIR) Tops Q2 EPS by 11c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.38), $0.11 better than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Hershey (HSY) PT Lowered to $206; RBC Capital: 'Struggling to See a Near Term Positive Inflection'
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04